NCT04720716 2026-03-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
Innovent Biologics (Suzhou) Co. Ltd.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Akeso